What is claimed is:

1. A method of treating a subject afflicted with rheumatoid arthritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof and an amount of methotrexate, wherein the amounts when taken together are effective to treat the subject.

2. The method of claim 1, wherein the amount of laquinimod or pharmaceutically acceptable salt thereof and the amount of methotrexate when taken together is more effective to treat the subject than when each agent is administered alone.

3. The method of claims 1 or 2, wherein the amount of laquinimod or pharmaceutically acceptable salt thereof and the amount of methotrexate when taken together is effective to reduce a clinical symptom of rheumatoid arthritis in the subject.

4. The method of any one of claims 1-3, wherein the pharmaceutically acceptable salt of laquinimod is laquinimod sodium.

5. The method of any one of claims 1-4, wherein the periodic administration of laquinimod or pharmaceutically acceptable salt thereof is effected orally.

6. The method of any one of claims 1-5, wherein the amount of laquinimod administered is 0.0005 - 10 mg/kg/day.

7. The method of any one of claims 1-5, wherein the amount of laquinimod administered is 0.1-2.0 mg/day.

8. The method of any one of claims 1-7, wherein the periodic administration of methotrexate is effected orally.

9. The method of any one of claims 1-8, wherein the amount of methotrexate administered is 0.02 - 1.0 mg/kg/day.

10. The method of any one of claims 1-8, wherein the amount of methotrexate administered is 1-3 mg/day.

11. The method of any one of claims 1-10, further comprising administration of nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, slow-acting drugs, gold compounds, hydroxychloroquine, sulfasalazine, combinations of slow-acting drugs, corticosteroids, cytotoxic drugs, immunosuppressive drugs and/or antibodies.

12. The method of any one of claims 1-11, wherein the periodic administration of laquinimod or pharmaceutically acceptable salt thereof and methotrexate substantially eliminates a symptom associated with rheumatoid arthritis.

13. The method of any one of claims 1-11, wherein the periodic administration of laquinimod or pharmaceutically acceptable salt thereof and methotrexate reduces the severity of a symptom associated with rheumatoid arthritis.

14. The method of any one of claims 1-11, wherein the periodic administration of laquinimod or pharmaceutically acceptable salt thereof and methotrexate reduces the number of joints affected by a symptom associated with rheumatoid arthritis.

15. The method of any one of claims 12-14, wherein the symptom is inflammation.

16. The method of any one of claims 12-14, wherein the symptom is formation of pannus tissue.

17. The method of any one of claims 12-14, wherein the symptom is cartilage damage.

18. The method of any one of claims 12-14, wherein the symptom is bone resorption.

19. The method of any one of claims 1-18, wherein the periodic administration of laquinimod or pharmaceutically acceptable salt thereof and methotrexate reduces proteinuria in the subject.

20. The method of claim 19, wherein proteinuria reduction is measured by 24 hour urine protein, 24 hour protein to creatinine ratio, spot protein to creatinine ratio, 24 hour urine albumin, 24 hour albumin to creatinine ratio, spot albumin to creatinine ratio, or by a urinary dipstick.

21. The method of any one of claims 1-20, wherein the periodic administration of laquinimod or pharmaceutically acceptable salt thereof and methotrexate eliminates urinary sediments.

22. The method of any one of claims 1-21, wherein each of the amount of laquinimod or pharmaceutically acceptable salt thereof when taken alone, and the amount of methotrexate when taken alone is effective to treat the subject.

23. The method of any one of claims 1-21, wherein either the amount of laquinimod or pharmaceutically acceptable salt thereof when taken alone, the amount of methotrexate when taken alone, or each such amount when taken alone is not effective to treat the subject.

24. The method of any one of claims 1-23, wherein subject is receiving methotrexate therapy prior to initiating laquinimod therapy..

25. The method of any one of claims 1-24, wherein the subject is a mammal.

26. The method of claim 25, wherein the mammal is human.

27. Laquinimod or pharmaceutically acceptable salt thereof for use in combination with methotrexate in treating a subject afflicted with rheumatoid arthritis.

28. A pharmaceutical composition comprising an amount of laquinimod or pharmaceutically acceptable salt thereof and an amount of methotrexate for use in treating a subject afflicted with rheumatoid arthritis.

What is claimed is:

1. Laquinimod or a pharmaceutically acceptable salt thereof for use in combination with methotrexate in treating a subject afflicted with rheumatoid arthritis.

2. A pharmaceutical composition comprising an amount of laquinimod or a pharmaceutically acceptable salt thereof and an amount of methotrexate for use in treating a subject afflicted with rheumatoid arthritis.

3. Laquinimod or the pharmaceutically acceptable salt for use of claim 1, wherein the treatment comprises periodically administering to the subject an amount of laquinimod or the pharmaceutically acceptable salt and an amount of methotrexate, wherein the amounts when taken together are effective to treat the subject.

4. Laquinimod or the pharmaceutically acceptable salt for use of claim 3, wherein the amount of laquinimod or pharmaceutically acceptable salt thereof and the amount of methotrexate when taken together is more effective to treat the subject than when each agent is administered alone.

5. Laquinimod or the pharmaceutically acceptable salt for use of claim 3 or 4, wherein the amount of laquinimod or pharmaceutically acceptable salt thereof and the amount of methotrexate when taken together is effective to reduce a clinical symptom of rheumatoid arthritis in the subject.

6. Laquinimod or the pharmaceutically acceptable salt for use of claims 3-5, wherein the pharmaceutically acceptable salt of laquinimod is laquinimod sodium.

7. Laquinimod or the pharmaceutically acceptable salt for use of any one of claims 3-6, wherein the periodic administration of laquinimod or the pharmaceutically acceptable salt thereof is effected orally.

8. Laquinimod or the pharmaceutically acceptable salt for use of any one of claims 3-7, wherein the amount of laquinimod administered is 0.0005 - 10 mg/kg/day or 0.1-2.0 mg/day.

9. Laquinimod or the pharmaceutically acceptable salt for use of any one of claims 3-8, wherein the amount of methotrexate administered is 0.02 - 1.0 mg/kg/day or 1-3 mg/day.

10. Laquinimod or the pharmaceutically acceptable salt for use of any one of claims 3-9, further wherein the treatment comprises administering a nonsteroidal anti-inflammatory drug (NSAID), a salicylate, a slow-acting drug, a gold compound, a hydroxychloroquine, a sulfasalazine, a combination of slow-acting drug, a corticosteroid, a cytotoxic drug, an immunosuppressive drug and/or an antibody.

11. Laquinimod or the pharmaceutically acceptable salt for use of any one of claims 3-10, wherein the periodic administration of laquinimod or the pharmaceutically acceptable salt thereof and methotrexate substantially eliminates a symptom or reduces the severity of a symptom associated with rheumatoid arthritis.

12. Laquinimod or the pharmaceutically acceptable salt for use of any one of claims 3-10, wherein the periodic administration of laquinimod or the pharmaceutically acceptable salt thereof and methotrexate reduces the number of joints affected by a symptom associated with rheumatoid arthritis.

13. Laquinimod or the pharmaceutically acceptable salt for use of any one of claims 3-12, wherein the periodic administration of laquinimod or the pharmaceutically acceptable salt thereof and methotrexate eliminates urinary sediments.

14. Laquinimod or the pharmaceutically acceptable salt for use of any one of claims 3-13, wherein each of the amount of laquinimod or the pharmaceutically acceptable salt thereof when

taken alone, and the amount of methotrexate when taken alone is effective to treat the subject.

15. Laquinimod or the pharmaceutically acceptable salt for use of any one of claims 3-14, wherein subject is receiving methotrexate therapy prior to initiating laquinimod therapy.